Increased plasma histidine activates hepatic STAT3, suppressing hepatic glucose production (HGP) in type 2 diabetes by inhibiting gluconeogenic enzymes and enhancing insulin’s effect, an action independent of central insulin signaling but reliant on central histamine pathways, revealing a novel target for diabetes treatment [27]. The gene discussed is INS; the disease is type 2 diabetes mellitus.